Block & Leviton and Robbins, Geller, Rudman & Dowd LLP are co-lead counsel in a proposed class action alleging that Defendants made materially false and misleading statements and omissions about Immunomedics’ receipt of and approach to handling a Form 483 from the Food and Drug Administration, which ultimately caused the Company’s new drug application to fail.

Gregg Edwards provided expert testimony relating to market efficiency, price impact, and class-wide damages for Immunomedics’ common stock.